While the life sciences industry has spent years unpacking the implications of copay accumulators and pharmacy benefit maximizers, a new frontier in benefit design is quietly taking shape: medical benefit maximizers. These strategies are becoming more prevalent within medical plans, yet many manufacturers and patient services teams do not fully recognize their prevalence or practical impact.

Valeris has identified over 200 brands currently targeted under medical benefit maximizer plans. If your brand appears on this list and your copay or patient services provider has not addressed these emerging tactics, it is time to take action.

“Medical benefit maximizers are reshaping how patients access therapy, and brands that have not assessed exposure risk facing avoidable disruptions,” said Michael Harris, Vice President of Patient Support Services Strategy at Valeris. “Review the list, understand where your brand stands, and act now. Waiting could put both patients and program performance at risk.”

Download the full list of impacted brands to determine whether your brand is affected. Manufacturers can reach out to the Valeris Patient Affordability team to uncover emerging payer tactics, assess exposure, and implement proactive strategies to safeguard both patient access and brand performance.